Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01168024 · ClinicalTrials.gov registry record · NA
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)
A NA study, sponsored by Osprey Medical.
- Terminated
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT01168024: Clinical Trial NA study, sponsored by Osprey Medical.
NCT01168024 is a NA study that was terminated before completion, run by Osprey Medical. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01168024, a NA study, was terminated before completion, sponsored by Osprey Medical.
- TERMINATED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.
Primary Outcome
CIN is defined as a post-procedure relative serum creatinine increase ≥ 25% or an absolute serum creatinine increase of ≥ 0.5 mg/dL).
Interventions
- DEVICE CINCOR™ System and contrast conservation unit (CCS-1)
- OTHER Standard of Care plus peri-procedural hydration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-11 |
| Phase | NA |
Why NCT01168024 stopped before completion
NCT01168024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which CINCOR™ System and contrast conservation unit (CCS-1) is the first listed.
NCT01168024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01168024 about?
NCT01168024 is a clinical study titled "Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)". The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.
What is the current status of trial NCT01168024?
This trial is currently terminated. It is a NA study. The enrollment target is 16 participants. The study started on 2012-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01168024?
The interventions under investigation include: CINCOR™ System and contrast conservation unit (CCS-1) (DEVICE), Standard of Care plus peri-procedural hydration (OTHER).
Who is sponsoring clinical trial NCT01168024?
This trial is sponsored by Osprey Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01168024's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia